HHS announces sweeping reorganization, including cuts of 10K workers

Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.

By Rebecca Pifer • March 27, 2025

How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.

By Michael Gibney • March 27, 2025

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Rx-to-OTC rule gets pushed back — again

A delay of the prescription-to-OTC rule signals health agencies’ ongoing reluctance to implement new regulations.

By Amy Baxter • March 26, 2025

Biogen plots new global headquarters in Kendall Square

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

By Jacob Bell • March 25, 2025

The industry heavyweight behind Novavax’s push to bounce back

As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

By Alexandra Pecci • March 25, 2025

Lilly, Novo expand DTC reach of obesity meds after compound win

The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.

By Amy Baxter • March 24, 2025

How pharma could feel the pain of a recession

Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

By Meagan Parrish • March 21, 2025

Vaccine makers face mRNA backlash as states seek further restrictions

A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.

By Amy Baxter • March 19, 2025

The key factors shaping China’s biopharma boom

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

By Alexandra Pecci • March 19, 2025

Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

By Kelly Bilodeau • March 17, 2025

Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

By Amy Baxter • March 17, 2025

Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

By Michael Gibney • March 13, 2025

Takeda’s $770M deal deepens Big Pharma’s omics push

The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

By Alexandra Pecci • March 13, 2025

IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

By Amy Baxter • March 12, 2025

The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

By Amy Baxter • March 11, 2025

Pricing transparency is in the spotlight — and that could be good news for drugmakers

An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

By Michael Gibney • March 11, 2025

What’s driving pharma’s layoffs in 2025

Familiar foes in the industry have claimed a slew of jobs in recent months.

By Meagan Parrish • March 10, 2025

As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges

Experts say cost and other barriers present challenges to returning to U.S. shores.

By Kelly Bilodeau • March 10, 2025

The time is ripe for pharma M&A. Why are drugmakers holding out?

The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.

By Michael Gibney • March 6, 2025

With patent losses on the horizon, Amgen refocuses its business strategy

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

By Alexandra Pecci • March 5, 2025

AbbVie gets into obesity with $350M deal for once-weekly shot

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

By Jonathan Gardner • March 5, 2025

Americans want to participate in clinical trials — so why don’t they?

A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

By Kelly Bilodeau • March 4, 2025

How pharma CEO pay shifted for these 4 companies last year

Top executives saw big pay changes in a year defined by slower M&A and political uncertainty.

By Amy Baxter • March 3, 2025

Teva targets schizophrenia to build on innovative medicines growth

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

By Meagan Parrish • Feb. 28, 2025

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

By Michael Gibney • Feb. 27, 2025